Correlation Between Vivos Therapeutics and Neuropace

Can any of the company-specific risk be diversified away by investing in both Vivos Therapeutics and Neuropace at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vivos Therapeutics and Neuropace into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Vivos Therapeutics and Neuropace, you can compare the effects of market volatilities on Vivos Therapeutics and Neuropace and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vivos Therapeutics with a short position of Neuropace. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vivos Therapeutics and Neuropace.

Diversification Opportunities for Vivos Therapeutics and Neuropace

0.87

Correlation Coefficient

Vivos Therapeutics  Neuropace

Very poor diversification

The 3 months correlation between Vivos and Neuropace is 0.87. Overlapping area represents the amount of risk that can be diversified away by holding Vivos Therapeutics and Neuropace in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neuropace and Vivos Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vivos Therapeutics are associated (or correlated) with Neuropace. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neuropace has no effect on the direction of Vivos Therapeutics i.e., Vivos Therapeutics and Neuropace go up and down completely randomly.

Pair Corralation between Vivos Therapeutics and Neuropace

Given the investment horizon of 90 days Vivos Therapeutics is expected to generate 1.53 times less return on investment than Neuropace. But when comparing it to its historical volatility, Vivos Therapeutics is 1.0 times less risky than Neuropace. It trades about 0.17 of its potential returns per unit of risk. Neuropace is currently generating about 0.26 of returns per unit of risk over similar time horizon. If you would invest  638.00  in Neuropace on October 26, 2024 and sell it today you would earn a total of  766.00  from holding Neuropace or generate 120.06% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Vivos Therapeutics  vs.  Neuropace

Vivos Therapeutics

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Vivos Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile basic indicators, Vivos Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Neuropace

Risk-Adjusted Performance

20 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Neuropace are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady fundamental indicators, Neuropace exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Vivos Therapeutics and Neuropace

The main advantage of trading using opposite Vivos Therapeutics and Neuropace positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vivos Therapeutics position performs unexpectedly, Neuropace can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neuropace will offset losses from the drop in Neuropace's long position.

The idea behind Vivos Therapeutics and Neuropace pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.